反应详情

Prepared from N-(3-chloro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl) -N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (0.160 g, 0.132 mmol), and N, N-diethylprop-2-yn-1-amine (0.0132 g, 0.118 mmol) according to the procedure for Example 6, Step B. The product was purified by Horizon reverse phase using Biotage 12M C18 column. The crude was loaded to the samplet with EtOAc and dried under vacuum. The product was eluted with 55-75% acetonitrile in water and was obtained as a white powder (20 mg, 26%). 1H NMR (CDCl3, 400 MHz) δ 10.14 (s, 1H), 8.50 (s, 1H), 8.46 (d, J=5.5 Hz, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.46 (m, 3H), 7.20 (d, J=8.6 Hz, 1H), 7.05 (t, J=8.8 Hz, 2H), 6.42 (d, J=5.5 Hz, 1H), 3.71 (s, 2H), 2.65 (q, J=7, 14 Hz, 4H), 1.77 (m, 4H), 1.13 (t, J=7.2 Hz, 6H). LRMS (ESI pos) m/e 591 (M+1).

1. customThe product was purified by Horizon reverse phase
2. customdried under vacuum
3. washThe product was eluted with 55-75% acetonitrile in water